Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion.
Rettinger E, Kreyenberg H, Merker M, Kuçi S, Willasch A, Bug G, Ullrich E, Wels WS, Bonig H, Klingebiel T, Bader P. Rettinger E, et al. Cytotherapy. 2014 Jun;16(6):835-44. doi: 10.1016/j.jcyt.2014.01.003. Epub 2014 Feb 28. Cytotherapy. 2014. PMID: 24582456
Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S, Wagner J, Friede ME, Pfirrmann V, Genßler S, Rettinger E, Buchholz CJ, Pfeifer H, Schubert R, Ottmann OG, Ullrich E, Bader P, Wels WS. Oelsner S, et al. Among authors: rettinger e. Int J Cancer. 2016 Oct 15;139(8):1799-809. doi: 10.1002/ijc.30217. Epub 2016 Jun 11. Int J Cancer. 2016. PMID: 27253354
Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience.
Willasch AM, Salzmann-Manrique E, Krenn T, Duerken M, Faber J, Opper J, Kreyenberg H, Bager R, Huenecke S, Cappel C, Bremm M, Pfirrmann V, Merker M, Ullrich E, Bakhtiar S, Rettinger E, Jarisch A, Soerensen J, Klingebiel TE, Bader P. Willasch AM, et al. Among authors: rettinger e. Bone Marrow Transplant. 2017 Feb;52(2):201-208. doi: 10.1038/bmt.2016.224. Epub 2016 Sep 19. Bone Marrow Transplant. 2017. PMID: 27643863 Clinical Trial.
The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation.
Heinze A, Grebe B, Bremm M, Huenecke S, Munir TA, Graafen L, Frueh JT, Merker M, Rettinger E, Soerensen J, Klingebiel T, Bader P, Ullrich E, Cappel C. Heinze A, et al. Among authors: rettinger e. Front Immunol. 2019 Dec 3;10:2816. doi: 10.3389/fimmu.2019.02816. eCollection 2019. Front Immunol. 2019. PMID: 31849984 Free PMC article.
ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
Heim C, Moser LM, Kreyenberg H, Bonig HB, Tonn T, Wels WS, Gradhand E, Ullrich E, Meister MT, Koerkamp MG, Holstege FCP, Drost J, Klusmann JH, Bader P, Merker M, Rettinger E. Heim C, et al. Among authors: rettinger e. Front Immunol. 2023 Aug 18;14:1228894. doi: 10.3389/fimmu.2023.1228894. eCollection 2023. Front Immunol. 2023. PMID: 37662907 Free PMC article.
Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation.
Heim C, Hartig L, Weinelt N, Moser LM, Salzmann-Manrique E, Merker M, Wels WS, Tonn T, Bader P, Klusmann JH, van Wijk SJL, Rettinger E. Heim C, et al. Among authors: rettinger e. Mol Ther Oncol. 2024 Apr 11;32(2):200802. doi: 10.1016/j.omton.2024.200802. eCollection 2024 Jun 20. Mol Ther Oncol. 2024. PMID: 38706988 Free PMC article.
47 results